Mobile

A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage Ib or II Non-Small Cell Lung Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002911-26

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to assess the feasibility of an adjuvant chemotherapy of pemetrexed, in combination with either cisplatin or carboplatin in patients with completely resected stage Ib or IIa/IIb NSCLC. Feasibility is defined as administration of pemetrexed randomly combined with either cisplatin or carboplatin for 4 consecutive cycles as defined per protocol.

Critère d'inclusion

  • Patients with histologically proven and completely resected (R0) stage Ib, IIa or IIb non-small cell lung cancer (NSCLC)

Liens